Decreased CSF levels of DOPAC have been shown to be an early marker for PD,22 and similarly HVA has been shown to be decreased in the CSF of PD patients compared to controls.23 Measuring CSF HVA and DOPAC as well as alpha‐synuclein levels may provide an important pharmacodynamic effect of Nilotinib treatment in PD. Here, SNCA is linked to Parkinson disease.